| Oct 8 |
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
|
| Sep 30 |
Traws Pharma announces results from its early stage trial for its COVID candidate
|
| Sep 30 |
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
|
| Sep 20 |
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
|
| Sep 17 |
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
|
| Aug 20 |
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
|
| Aug 15 |
Traws Pharma GAAP EPS of -$4.87
|
| Aug 15 |
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
|
